NCT04348747 uses dendritic cell vaccines targeting HER2/HER3, and the combination with pembrolizumab can strengthen the immune system and enhance the tumor immune responses, which is favorable to shrinking cancer. The gene discussed is ERBB2; the disease is cancer.